Keytruda primary u's patent expires 2028?

Yes, the primary U.S. patents covering Keytruda (pembrolizumab) are slated to expire in 2028. That date marks the end of the original 20‑year term granted to the filing date of the earliest key patent that defines the drug’s composition of matter and its use for treating melanoma and other cancers.

What that means in practice

Key points for patients and prescribers

• Availability of biosimilars: Even after the primary patents expire, the drug is still protected by other patents covering manufacturing processes, formulation, labeling, and specific use cases. Biosimilar developers will need to navigate these secondary patents, which can delay entry into the market.
• Pricing: The end of the primary patents does not automatically lead to a price drop. Competing biosimilars typically face a long path to approval and market acceptance, and payer contracts can maintain high list prices until competition intensifies.
• Insurance coverage: Most insurers still cover Keytruda under preferred formulary slots, so patients usually do not see a cost difference until a biosimilar becomes widely available and negotiated into the formulary.

If you’re a prescriber or patient wondering what to expect

• Stay informed: Monitor FDA approvals and payer guidelines for biosimilar listings.
• Discuss options: If you’re eligible, talk to your provider about the availability of a biosimilar, which could be a cost‑effective alternative once it’s approved and covered.
• Keep your records: For insurance claims, having the exact date of a biosimilar’s market entry can help in case of billing or reimbursement issues.

Feel free to let me know if you’d like more detail on any of these points—such as the specific secondary patents, the current status of biosimilar approvals, or how pricing typically shifts when a biosimilar enters the market.